Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: HAE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $85.91
1 Year Target Price $85.91
| 3 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.18% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.01B USD | Price to earnings Ratio 24.55 | 1Y Target Price 85.91 |
Price to earnings Ratio 24.55 | 1Y Target Price 85.91 | ||
Volume (30-day avg) 10 | Beta 0.3 | 52 Weeks Range 47.32 - 85.48 | Updated Date 12/8/2025 |
52 Weeks Range 47.32 - 85.48 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.67% | Operating Margin (TTM) 21.02% |
Management Effectiveness
Return on Assets (TTM) 6.36% | Return on Equity (TTM) 19.47% |
Valuation
Trailing PE 24.55 | Forward PE 10.04 | Enterprise Value 4823334807 | Price to Sales(TTM) 3.02 |
Enterprise Value 4823334807 | Price to Sales(TTM) 3.02 | ||
Enterprise Value to Revenue 3.66 | Enterprise Value to EBITDA 13.61 | Shares Outstanding 46809672 | Shares Floating 46121102 |
Shares Outstanding 46809672 | Shares Floating 46121102 | ||
Percent Insiders 1.18 | Percent Institutions 113.52 |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics Corporation was founded in 1971. It is a global leader in blood and plasma collection, processing, and management solutions. Key milestones include the development of its first automated plasma collection system and expansion into various therapeutic areas like autologous blood recovery and cellular therapy.
Core Business Areas
- Plasma: Develops and manufactures systems and consumables for the collection and processing of plasma, a critical component in life-saving therapies and pharmaceuticals. This includes plasma collection devices and related disposables.
- Blood: Offers solutions for blood collection, processing, and management, including automated systems for blood component collection, apheresis, and autologous blood recovery in surgical settings.
- Transfusion: Provides technologies and services that enhance the safety and efficiency of blood transfusions, focusing on blood management solutions and pathogen reduction technologies.
- Cellular Therapy: Developing and offering solutions that support the emerging field of cellular therapies, including apheresis systems for cell collection and processing for regenerative medicine and other advanced treatments.
Leadership and Structure
Haemonetics Corporation is led by a management team comprising a Chief Executive Officer, Chief Financial Officer, and other senior executives responsible for global operations, research and development, sales, and marketing. The company operates through various divisions and regional offices to serve its global customer base.
Top Products and Market Share
Key Offerings
- PCS 2 System: An automated system for plasma collection. It is a flagship product in their plasma business. Competitors include Terumo Blood and Cell Technologies and Fresenius Kabi.
- TEPHRA Solutions: A portfolio of apheresis devices and consumables for blood collection and therapeutic apheresis. Competitors include Terumo Blood and Cell Technologies and Haemonetics' own legacy products.
- Nexsysu00ae System: A blood management system for hospitals, aiding in inventory management and transfusion decisions. Competitors include Haemonetics' older systems and other hospital information system providers.
- Marathonu00ae: A system for autologous blood recovery during surgical procedures. Competitors include Fresenius Kabi and other medical device manufacturers.
Market Dynamics
Industry Overview
The blood and plasma processing industry is driven by an increasing demand for plasma-derived therapies, a growing need for safe blood transfusions, and advancements in cellular therapies. The industry is characterized by stringent regulatory requirements and a focus on efficiency and patient safety.
Positioning
Haemonetics Corporation is a well-established player with a strong reputation for its innovative technologies in plasma and blood collection. Its competitive advantages lie in its integrated solutions, established customer relationships, and ongoing investment in R&D to address evolving healthcare needs, particularly in the cellular therapy space.
Total Addressable Market (TAM)
The global market for blood and plasma collection, processing, and transfusion is substantial, estimated to be in the tens of billions of dollars annually. Haemonetics Corporation is well-positioned to capture a significant portion of this market, particularly in its core segments of plasma collection and blood management, with increasing focus on the high-growth cellular therapy market.
Upturn SWOT Analysis
Strengths
- Established brand reputation and long-standing customer relationships.
- Diversified product portfolio serving critical healthcare needs.
- Strong commitment to research and development, driving innovation.
- Global presence and distribution network.
- Expertise in apheresis and plasma processing technologies.
Weaknesses
- Reliance on a few key product lines.
- Potential for longer sales cycles for capital equipment.
- Competition from larger, more diversified healthcare companies.
- Sensitivity to regulatory changes and reimbursement policies.
Opportunities
- Growing demand for plasma-derived therapies and vaccines.
- Expansion of cellular and gene therapy markets.
- Increasing adoption of advanced blood management solutions in hospitals.
- Geographic expansion into emerging markets.
- Strategic partnerships and acquisitions to enhance product offerings.
Threats
- Intensifying competition from existing and new players.
- Economic downturns impacting healthcare spending.
- Changes in regulatory landscapes and compliance costs.
- Disruptions in supply chains for critical components.
- Technological obsolescence of existing products.
Competitors and Market Share
Key Competitors
- Terumo Blood and Cell Technologies (TRMO)
- Fresenius Kabi (FRY)
- Grifols S.A. (GRF)
Competitive Landscape
Haemonetics benefits from its established position and technological expertise, particularly in apheresis and plasma. However, it faces intense competition from large multinational corporations that may have broader product portfolios and greater financial resources. Its ability to innovate and adapt to evolving market needs, especially in cellular therapies, will be crucial for maintaining and growing its market share.
Major Acquisitions
Pall Corporation's Global Medical Business
- Year: 2020
- Acquisition Price (USD millions): 500
- Strategic Rationale: To strengthen its portfolio in transfusion medicine and expand its reach in hospital markets, particularly in blood management solutions and pathogen reduction technologies.
Creative Medical Technologies
- Year: 2022
- Acquisition Price (USD millions):
- Strategic Rationale: Although not a full acquisition, Haemonetics invested in and partnered with Creative Medical Technologies to advance its capabilities in the cellular therapy space, focusing on bone marrow and stem cell applications.
Growth Trajectory and Initiatives
Historical Growth: Haemonetics has experienced consistent historical growth, driven by its established position in the blood and plasma markets and its focus on expanding its product lines and geographic reach. The company has benefited from the increasing demand for its core products and services.
Future Projections: Analyst projections for Haemonetics typically indicate continued revenue growth, driven by the expanding plasma-derived therapies market, the nascent but promising cellular therapy sector, and potential market penetration in under-served regions. (Specific future growth projections would be sourced from analyst reports.)
Recent Initiatives: Recent initiatives include strategic acquisitions to bolster its cellular therapy offerings, investments in R&D for next-generation products, and efforts to optimize its global supply chain and manufacturing operations to meet growing demand.
Summary
Haemonetics Corporation is a strong player in the critical blood and plasma collection and processing market, with a robust product portfolio and established customer relationships. Its strategic focus on innovation and expansion into the burgeoning cellular therapy sector positions it for continued growth. However, it must navigate intense competition and evolving regulatory landscapes to maintain its leadership. Managing R&D investment effectively and adapting to technological advancements will be key for sustained success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Haemonetics Corporation Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Numerical data presented is based on publicly available information and may be subject to change. Market share figures are estimates and may vary. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3023 | Website https://www.haemonetics.com |
Full time employees 3023 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.